ADMA Biologics Financial Statements From 2010 to 2022

ADMA
 Stock
  

USD 3.34  0.02  0.60%   

ADMA Biologics financial statements provide useful quarterly and yearly information to potential ADMA Biologics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on ADMA Biologics financial statements helps investors assess ADMA Biologics' valuation, profitability, and current liquidity needs.
We have found one hundred two available fundamental signals for ADMA Biologics, which can be analyzed and compared to other ratios and to its rivals. Make sure you validate all of ADMA Biologics prevailing market performance against the performance between 2010 and 2022 to make sure the company can sustain itself in the future.
ADMA Biologics Average Assets are projected to increase significantly based on the last few years of reporting. The past year's Average Assets were at 245.84 Million. The current year Average Equity is expected to grow to about 126.3 M, whereas Net Income Per Employee is forecasted to decline to (146.7 K).
  
Check ADMA Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ADMA Biologics main balance sheet or income statement drivers, such as Direct Expenses of 86.1 M, Cost of Revenue of 86.1 M or Gross Profit of 1.3 M, as well as many exotic indicators such as Long Term Debt to Equity of 0.69, PPandE Turnover of 2.19 or Receivables Turnover of 3.97. ADMA Biologics financial statements analysis is a perfect complement when working with ADMA Biologics Valuation or Volatility modules. It can also supplement ADMA Biologics' financial leverage analysis and stock options assessment as well as various ADMA Biologics Technical models . Please continue to the analysis of ADMA Biologics Correlation against competitors.

ADMA Biologics Revenues

87.33 Million

ADMA Biologics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Trade and Non Trade Receivables30.8 M28.6 M6.5 M
Increasing
Slightly volatile
Property Plant and Equipment Net62.8 M58.2 M20.8 M
Increasing
Slightly volatile
Trade and Non Trade Payables13.4 M12.4 M5.4 M
Increasing
Slightly volatile
Liabilities Non Current113 M104.7 M45.1 M
Increasing
Slightly volatile
Current Liabilities32.8 M30.4 M11.2 M
Increasing
Slightly volatile
Total Liabilities145.7 M135.1 M56.3 M
Increasing
Slightly volatile
Investments Current6.1 M6.2 M4.8 M
Increasing
Slightly volatile
Investments6.1 M6.2 M4.8 M
Increasing
Slightly volatile
Inventory134.6 M124.7 M33.9 M
Increasing
Slightly volatile
Goodwill and Intangible Assets5.6 M5.3 M7.5 M
Decreasing
Slightly volatile
Shareholders Equity USD152.3 M141.2 M38.6 M
Increasing
Slightly volatile
Shareholders Equity152.3 M141.2 M38.6 M
Increasing
Slightly volatile
Deferred Revenue2.5 M2.1 M2.2 M
Increasing
Slightly volatile
Total Debt USD103 M95.5 M40.2 M
Increasing
Slightly volatile
Debt Non Current102.4 M94.9 M39.6 M
Increasing
Slightly volatile
Debt Current765 K591.1 K699.7 K
Increasing
Very volatile
Total Debt103 M95.5 M40.2 M
Increasing
Slightly volatile
Cash and Equivalents USD42 M51.1 M25.3 M
Increasing
Slightly volatile
Cash and Equivalents55.1 M51.1 M25.5 M
Increasing
Slightly volatile
Assets Non Current72.9 M67.5 M26.1 M
Increasing
Slightly volatile
Current Assets225.2 M208.7 M68.9 M
Increasing
Slightly volatile
Total Assets298.1 M276.3 M94.9 M
Increasing
Slightly volatile
Accounts Payable13.4 M12.4 M5.4 M
Increasing
Slightly volatile
Receivables30.8 M28.6 M6.5 M
Increasing
Slightly volatile
Inventories134.6 M124.7 M33.9 M
Increasing
Slightly volatile

ADMA Biologics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Weighted Average Shares Diluted150.6 M139.6 M41.7 M
Increasing
Slightly volatile
Weighted Average Shares150.6 M139.6 M41.7 M
Increasing
Slightly volatile
Selling General and Administrative Expense46.3 M42.9 M17.1 M
Increasing
Slightly volatile
Research and Development Expense4.2 M3.6 M4.9 M
Increasing
Very volatile
Revenues USD87.3 M80.9 M23.8 M
Increasing
Slightly volatile
Revenues87.3 M80.9 M23.8 M
Increasing
Slightly volatile
Operating Expenses64.2 M59.5 M27.8 M
Increasing
Slightly volatile
Interest Expense14.1 M13.1 M5.1 M
Increasing
Slightly volatile
Gross Profit1.3 M1.2 M(3.6 M)
Decreasing
Slightly volatile
Cost of Revenue86.1 M79.8 M27.3 M
Increasing
Slightly volatile
Direct Expenses86.1 M79.8 M27.3 M
Increasing
Slightly volatile

ADMA Biologics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Share Based Compensation2.8 M3.5 M1.6 M
Increasing
Slightly volatile
Net Cash Flow Investment Acquisitions and Disposals6.7 M6.2 M1.6 M
Increasing
Slightly volatile
Net Cash Flow from Investing(13.9 M)(13.5 M)(3 M)
Decreasing
Slightly volatile
Net Cash Flow from Financing130.6 M121 M51.2 M
Increasing
Slightly volatile
Issuance Repayment of Debt Securities (35.2 K)(34.3 K)7.2 M
Increasing
Stable
Issuance Purchase of Equity Shares130.7 M121.1 M47.8 M
Increasing
Slightly volatile
Net Cash Flow Business Acquisitions and Disposals11.2 M11.2 M12.3 M
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(5 M)(4.8 M)3.5 M
Decreasing
Very volatile
Depreciation Amortization and Accretion5.9 M5.5 M2.1 M
Increasing
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Tangible Assets Book Value per Share2.41.9423.5853
Decreasing
Slightly volatile
Sales per Share0.730.57990.8427
Decreasing
Slightly volatile
Price to Sales Ratio2.52.4319.8013
Decreasing
Slightly volatile
Price to Book Value2.011.95611.1515
Decreasing
Very volatile
Gross Margin1.491.449515.1604
Decreasing
Slightly volatile
Debt to Equity Ratio0.690.6722.7012
Decreasing
Very volatile
Current Ratio5.976.8715.2299
Increasing
Slightly volatile
Book Value per Share0.961.0111.0245
Decreasing
Stable
Asset Turnover0.290.33450.2372
Increasing
Slightly volatile
Total Assets Per Share1.451.41083.0302
Decreasing
Slightly volatile
Receivables Turnover3.973.87159.0361
Decreasing
Slightly volatile
Inventory Turnover0.790.77351.386
Increasing
Stable
PPandE Turnover2.191.74962.0701
Decreasing
Stable
Cash and Equivalents Turnover1.631.51280.7115
Increasing
Slightly volatile
Accounts Payable Turnover7.436.88783.5375
Increasing
Slightly volatile
Accrued Expenses Turnover5.085.984.6103
Increasing
Slightly volatile
Long Term Debt to Equity0.690.6722.5157
Decreasing
Very volatile
Quick Ratio3.132.37053.1548
Decreasing
Stable
Net Current Assets as percentage of Total Assets56.6764.560847.3114
Increasing
Slightly volatile
Revenue to Assets0.250.2930.2335
Increasing
Stable

ADMA Biologics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Working Capital192.4 M178.4 M57.6 M
Increasing
Slightly volatile
Tangible Asset Value292.4 M271 M91.9 M
Increasing
Slightly volatile
Market Capitalization226.6 M276.1 M131.2 M
Increasing
Slightly volatile
Invested Capital Average282.6 M261.9 M85.8 M
Increasing
Slightly volatile
Invested Capital307.5 M285 M94.6 M
Increasing
Slightly volatile
Enterprise Value268.8 M336.6 M146.7 M
Increasing
Slightly volatile
Average Equity126.3 M117 M34.3 M
Increasing
Slightly volatile
Average Assets265.3 M245.8 M87 M
Increasing
Slightly volatile
Revenue Per Employee122.5 K153.6 K104.6 K
Increasing
Very volatile

ADMA Biologics Fundamental Market Drivers

Cash And Short Term Investments51089118.00

ADMA Biologics Upcoming Events

Upcoming Quarterly Report24th of March 2022
Next Financial Report11th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

About ADMA Biologics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include ADMA Biologics income statement, its balance sheet, and the statement of cash flows. ADMA Biologics investors use historical funamental indicators, such as ADMA Biologics's revenue or net income, to determine how well the company is positioned to perform in the future. Although ADMA Biologics investors may use each financial statement separately, they are all related. The changes in ADMA Biologics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ADMA Biologics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on ADMA Biologics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in ADMA Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Deferred Revenue2.1 M2.5 M
Cost of Revenue79.8 M86.1 M
Revenues80.9 M87.3 M
Revenue to Assets 0.29  0.25 
Revenue Per Employee153.6 K122.5 K

Be your own money manager

Our tools can tell you how much better you can do entering a position in ADMA Biologics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Pair Correlation Now

   

Pair Correlation

Compare performance and examine fundamental relationship between any two equity instruments
All  Next Launch Module

Pair Trading with ADMA Biologics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ADMA Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ADMA Biologics will appreciate offsetting losses from the drop in the long position's value.

Moving together with ADMA Biologics

+0.77ABBVAbbVie Inc TrendingPairCorr
The ability to find closely correlated positions to ADMA Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ADMA Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ADMA Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ADMA Biologics to buy it.
The correlation of ADMA Biologics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ADMA Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ADMA Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ADMA Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Please continue to the analysis of ADMA Biologics Correlation against competitors. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for analysis

When running ADMA Biologics price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Is ADMA Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
661.2 M
Quarterly Revenue Growth YOY
0.99
Return On Assets
(0.11) 
Return On Equity
(0.69) 
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine ADMA Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.